IP Library Granted Patent US 6,866,871
Granted Patent B2
US 6,866,871 · App. 10/277,298 · Granted Mar 15, 2005

Dry powders of metal-containing compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,866,871
App. No.
10/277,298
Granted
Mar 15, 2005
Kind
B2
Abstract

Dry powders of metal-containing compounds are disclosed. Methods of preparing and using the dry powders, particularly in the treatment of a subject having a condition, are also disclosed. The metal-containing material can be, for example, an antimicrobial material, an antibacterial material, an anti-inflammatory material, an anti-fungal material, an anti-viral material, an anti-cancer material, a pro-apoptosis material, and/or an MMP modulating material. In certain embodiments, the metal-containing material is an atomically disordered, silver-containing material.

Claims (24)

1. A method of treating a human or animal subject having a condition, the method comprising:

contacting an area of the subject having the condition with an antimicrobial nanocrystalline metal-containing compound by dry inhaling a safe and therapeutically effective amount of a free-standing powder of the antimicrobial nanocrystalline metal-containing compound, wherein:

the condition is selected from the group consisting of bacterial respiratory conditions, microbial respiratory conditions, fungal respiratory conditions and viral respiratory conditions,

the antimicrobial nanocrystalline metal-containing compound contains a metal selected from the group consisting of silver, gold, platinum and palladium, and

the free-standing powder of the antimicrobial nanocrystalline metal-containing compound has an average particle size of less than about two microns.

2. The method of claim 1 , wherein the antimicrobial nanocrystalline metal-containing compound is selected from the group consisting of silver, gold, platinum, palladium, and alloys thereof.

3. The method of claim 1 , wherein the antimicrobial nanocrystalline metal-containing compound is an oxide, nitride, boride, halide or hydride of silver, gold, platinum or palladium.

4. The method of claim 1 , wherein the antimicrobial nanocrystalline metal-containing compound comprises silver.

5. The method of claim 1 , antimicrobial nanocrystalline metal-containing compound comprises an ionic compound of silver, gold, platinum or palladium.

6. The method of claim 1 , wherein the antimicrobial nanocrystalline metal-containing compound comprises atoms, molecules or clusters of silver, gold, platinum or palladium.

7. The method of claim 1 , wherein the antimicrobial nanocrystalline metal-containing compound comprises an atomically disordered, crystalline compound of silver, gold, platinum or palladium.

8. The method of claim 1 , wherein the condition is selected from the group consisting of bronchitis, tuberculosis, pneumonia, sinusitis, and pharyngitis.

9. The method of claim 1 , wherein the free-standing powder is inhaled with a dry powder inhaler.

10. The method of claim 1 , wherein the free-standing powder has an average particle size of about one micron or less.

11. The method of claim 1 , wherein the condition is a bacterial respiratory condition.

12. The method of claim 1 , wherein the condition is a microbial respiratory condition.

13. The method of claim 1 , wherein the condition is a fungal respiratory condition.

14. The method of claim 1 , wherein the condition is a viral respiratory condition.

15. The method of claim 1 , wherein the condition is bronchitis.

16. The method of claim 1 , wherein the condition is tuberculosis.

17. The method of claim 1 , wherein the condition is pneumonia.

18. The method of claim 1 , wherein the condition is sinusitis.

19. The method of claim 1 , wherein the condition is pharyngitis.

20. The method of claim 1 , wherein the condition is pneumonia and the antimicrobial nanocrystalline metal-containing compound comprises silver.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2004
From: BURRELL, ROBERT E.
To: NUCRYST PHARMACEUTICALS CORP.
Reel/Frame 014727/0827 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2003
From: GILLIS, SCOTT H.; SCHECHTER, PAUL
To: NUCRYST PHARMACEUTICALS CORP.
Reel/Frame 014230/0960 →